Morgan Stanley Downgrades Humana to Underweight Despite $1.87M Tejara Stake
On Feb. 2 Morgan Stanley downgraded Humana to Underweight from Equal Weight with the stock at $195.20. Despite this, Tejara Capital acquired 7,200 shares (~$1.87M) and multiple hedge funds opened new positions even as Humana's stock swung between a $315.35 high and $191.39 low last year.
1. Humana’s Value-Based Care Report Highlights Tangible Health Improvements
In its latest Value-Based Care By the Numbers Report covering calendar-year 2024, Humana demonstrated that Medicare Advantage members in value-based arrangements experienced 24.3% fewer inpatient admissions compared with peers in traditional Medicare. Emergency department visits fell by 13.4%, and hospital admissions dropped by 7.6% for those treated under these models. The report further shows increased screening rates—breast cancer and colorectal cancer screenings rose by double-digit percentages—and higher adherence to statin therapy among members with cardiovascular disease. Seniors receiving care from a dedicated value-based primary care team logged 20% more annual visits and enjoyed a 75% continuity of care rate, versus 55% for fee-for-service patients. Patient satisfaction also climbed, with net promoter scores 13 points higher among value-based care participants, underscoring both clinical and experiential gains.
2. AI-Powered Agent Assist Poised to Transform Member Support
Humana has rolled out its Agent Assist tool—developed with Google Cloud’s Vertex AI and Gemini Enterprise—to more than 20,000 member advocates handling up to 80 million annual inquiries. Since pilot deployment in October 2025, the system has generated real-time call summaries, surfaced eligibility details within seconds, and provided compliance prompts to ensure accuracy. Early internal metrics suggest a 30% reduction in average handle time and a 25% drop in escalation rates for complex benefit questions. With full service-center integration slated for later in 2026, Humana expects the platform to cut manual research by half, boost first-contact resolution by 15%, and maintain a human-in-the-loop approach that preserves advocates’ decision-making authority and empathy in every interaction.